CARMELINA: Linagliptin Reassures for DPP-4 Inhibitors in Diabetes CARMELINA: Linagliptin Reassures for DPP-4 Inhibitors in Diabetes
The CARMELINA safety study for the dipeptidyl peptidase-4 inhibitor linagliptin not only shows no increase in CV, kidney, or safety events but also allays fears over a class heart failure effect.Medscape Medical News
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news
More News: Cardiology | Diabetes | Endocrinology | Health | Heart | Heart Failure | Study | Urology & Nephrology